Leavell Investment Management Inc. lowered its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 2.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,021 shares of the biopharmaceutical company’s stock after selling 450 shares during the quarter. Leavell Investment Management Inc.’s holdings in Bristol-Myers Squibb were worth $1,171,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Welch Investments LLC grew its holdings in Bristol-Myers Squibb by 3.9% during the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 79 shares in the last quarter. Crestwood Advisors Group LLC bought a new position in Bristol-Myers Squibb in the 1st quarter valued at $116,000. Blue Chip Partners Inc. grew its stake in Bristol-Myers Squibb by 0.8% in the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 17 shares during the period. American National Bank grew its stake in Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 225 shares during the period. Finally, Proficio Capital Partners LLC grew its stake in Bristol-Myers Squibb by 29.6% in the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 504 shares during the period. Institutional investors and hedge funds own 68.88% of the company’s stock.

Shares of Bristol-Myers Squibb Company (NYSE BMY) traded up 1.16% during mid-day trading on Friday, reaching $63.74. The company had a trading volume of 5,404,324 shares. The firm has a 50 day moving average of $58.94 and a 200-day moving average of $56.02. The stock has a market capitalization of $104.53 billion, a P/E ratio of 23.28 and a beta of 1.18. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.75. Bristol-Myers Squibb also was the target of some unusual options trading on Thursday. Stock traders purchased 781 put options on the stock. This is an increase of approximately 117% compared to the typical volume of 360 put options.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the previous year, the company posted $0.69 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 5.6% on a year-over-year basis. Analysts forecast that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.45%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 56.73%.

A number of research analysts have issued reports on the company. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price objective for the company in a research note on Wednesday. BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Jefferies Group LLC restated a “buy” rating and issued a $72.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Finally, Cowen and Company set a $65.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $62.17.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Theodore R. Samuels II purchased 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, with a total value of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Leavell Investment Management Inc. Sells 450 Shares of Bristol-Myers Squibb Company (BMY)” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/leavell-investment-management-inc-sells-450-shares-of-bristol-myers-squibb-company-bmy/1599277.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.